Prelude Therapeutics Incorporated (PRLD)
NMS – Real Time Price. Currency in USD
4.38
+0.28 (6.83%)
At close: Jun 26, 2026, 4:00 PM EDT
4.38
-0.00 (-0.00%)
After-hours: Jun 26, 2026, 4:31 PM EDT
Find any stock by ticker or company name

NMS – Real Time Price. Currency in USD
4.38
+0.28 (6.83%)
At close: Jun 26, 2026, 4:00 PM EDT
4.38
-0.00 (-0.00%)
After-hours: Jun 26, 2026, 4:31 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $21.8M significantly exceed its total debt $17.7M, ensuring strong financial flexibility
Total current assets $84.6M exceed Total current liabilities $41.7M, highlighting excellent liquidity
Debt-to-equity ratio (0.3) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$21.7M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.03 | 6.05 | 10 | |
| Quick ratio | 2.03 | 5.63 | 10 | |
| Debt to Equity | 0.29 | 0.30 | 8.0 | |
| Debt to Assets | 0.15 | 1.04 | 8.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | 7M | 12M | 17M |
| Gross Profit | -3M | -1M | 5M | 10M | 15M |
| Operating Income | -124M | -132M | -140M | -105M | -84M |
| Net Income | -115M | -122M | -127M | -99M | -78M |
| EBITDA | -120M | -131M | -138M | -103M | -82M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 42.07 | 5.5 |
| Next quarter | 284.62 | 104.81 | 10 |
| Current year | 134.31 | 50 | 10 |
| Next year | 87.5 | 4.91 | 7.0 |
| Weighted average score | 8.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -18.78 | 36.9 | 35 | -193.79 | 5.5 |
| Y/Y | 999 | 67.63 | 69.05 | 36.74 | 10 |
| 3y average | 690.48 | 3.95 | 19.08 | 8.14 | 7.3 |
| 5y average | 813.89 | -17.52 | 20.71 | -12 | 5.5 |
| Weighted average score | 7.1 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |